By Jennifer Moore, LRG Member I was waiting in line to pick up a new prescription for Gleevec when my husband ran in and told me to forget it. After two surgeries, a year on 400 mg of Gleevec and a miserable few weeks on Sutent, Owen had a few rogue tumors that continued to […]
BLU-285, Clinical Trial, D824V, Jennifer Moore, member stories, OHSU, Owen Moore
At the most basic level, cancer patients join clinical trials because of perceived value and perceived cost. In this context, perceived cost refers to more than just financial cost, although that is important. Perceived cost includes not only financial costs, but also includes other things such as perceived side effects, any cost in time, which […]
Clinical Trials, GIST patients
The Life Raft Group had the pleasure of hosting the global New Horizons GIST meeting this year in our Wayne, New Jersey office. This international meeting traditionally gathers global GIST advocates with the shared vision to unify and support patient advocacy efforts and hear advances in research and treatment of GIST. 31 participants from 15 […]
Amy Bruno-Lindner, Blueprint Medicines, Contactgroep GIST, Dana Farber Cancer Institute, David Josephy, Dr. Bill Tap, Dr. Carl Asche, Dr. Ciara Kelly, Dr. Suzanne George, Dr. Theresa Mullin, Fundación GIST México, Gerard van Oortmerssen, Ginger Sawyer, GIST Support International, GIST Support Osterreich, Markus Wartenberg, Martin Wettstein, Memorial Sloan-Kettering Cancer Center, New Horizons, NewHorizons2017, Novartis, Pat Garcia, Pfizer, Piga Fernandex, Rodrigo Salas, The Max Foundation
The Life Raft Group Clinic Trials Database currently lists 31 trials that are open that are or could be of interest to GIST patients. Many of the most interesting of these new drugs are in phase I clinical trials. Several new approaches are being tried including drugs that target a specific mutation or subtype, immunotherapy, […]
BLU-285, Blueprint Medicines, Clinical Trials, CTOS 2017, D842V mutation, DCC-2618, Deciphera Pharmaceuticals, Dr. Filip Janku, Dr. Michael Heinrich, MD Anderson Cancer Center, Resistance